Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tao Capital Partners
BioCentury | Jan 4, 2023
Deals
Jan. 3 Quick Takes: Gilead, Evoq in lymphatic delivery deal
Plus: Vera dips on postmarket readout and updates from ArriVent, Apnimed, CStone, Legend and more
BioCentury | Sep 7, 2022
Finance
Sept. 7 Quick Takes: Arch-backed Orbital launches with RNA platform
Plus Arpeggio raises $17M series A for transcriptional mechanisms, and updates from Equillium, BoomRay, Zealand and more
BioCentury | Jun 4, 2022
Regulation
June 3 Quick Takes: myocarditis risk weighs on Novavax stock
Plus venture money for Vizgen, Watchmaker, Latch Bio, Endpoint Health
BioCentury | May 5, 2022
Regulation
May 4 Quick Takes: FDA clears Fujirebio’s Alzheimer’s diagnostic
Plus Jazz licenses sleep disorder therapy from Sumitomo and updates from Apnimed, Phathom, AZ, Kezar
BioCentury | Apr 13, 2022
Data Byte
Largest venture rounds of 1Q22
Last quarter’s top 10 venture financings raked in a combined $2.4 billion
BioCentury | Dec 17, 2021
Finance
Verge prepares for clinical debut with strategics in $98M series B
Financing will also help expand the neuro company’s AI capabilities to include biomarker discovery, patient enrichment
BioCentury | Nov 10, 2021
Product Development
Nov. 9 Quick Takes: Arbor’s $215M round attracts Temasek, Ally Bridge, TCG
Janssen trims Alkermes deal, EU moves to standardize HTA, plus GE Healthcare, Biogen, Amylyx and more
BioCentury | Apr 28, 2021
Product Development
April 27 Quick Takes: Merck, Gilead move to expand access to COVID-19 antivirals; plus Exscientia-Softbank, Lilly, Aldeyra, LogicBio, Canbridge, Daiichi, Ultivue, Provention
Initiatives by Merck & Co. Inc. (NYSE:MRK) and Gilead Sciences Inc. (NASDAQ:GILD) will expand availability of the companies’ antivirals in India as the country’s COVID-19 crisis
BioCentury | Apr 8, 2021
Finance
Venture rounds for Icosavax, Nucleix, Vizgen, Inscripta, Metagenomi and Volastra
Vaccine developer Icosavax Inc. raised $100 million in a series B round led by RA Capital Management. New investors Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant
BioCentury | Mar 26, 2021
Finance
March 25 Quick Takes: Lava flows down on first day after $100.5M IPO; plus Scipher, Eliem, Brii, Bioheng, RiverVest, JSR Life Science and Apnimed
Lava dips on first day after raising $100.5M IPOLava Therapeutics B.V. (NASDAQ:LVTX) fell $0.70 to $14.30 in its first day of trading on NASDAQ after raising $100.5 million through the sale of 6.7
Items per page:
1 - 10 of 12